transplant rejection

(redirected from Rejection of the graft)

transplant rejection

Graft rejection, organ rejection, tissue rejection Immunology The constellation of host immune responses evoked when an allograft tissue is transplanted into a recipient; rejection phenomena may be minimized by optimal matching of MHC antigens and ABO blood groups and ameliorated with immunosuppressants–eg, cyclosporin, tacrolimus, rapamycin Exceptions of TR Corneal transplants, identical twins. See Graft-versus-host disease, HLA, MHC, Tissue typing.
References in periodicals archive ?
suggested that MSCs could participate in the restoration of niches for donor hematopoietic cells or have an immunomodulatory effect, preventing repeated rejection of the graft, and perhaps intraosseous implantation of MSCs contributes to the success of the second transplantation of hematopoietic stem cells and patient survival.
There was no case of infection or rejection of the graft.
The authors reported that the heart transplant primed a proinflammatory, anti-male T cell immune response, but that it was insufficient in quantity to mediate acute rejection of the graft. They used a TCR-transgenic to show that the male grafts do express enough antigen to be rejected if sufficient numbers of high-affinity T cells are present.
b) can(?) violate the classical transplant concept of allogenic rejection of the graft (non-HLA matched) for at least one month (period of observation);
Transplanted animals were divided into two groups: thosegiven the immunosuppressive drugs cyclosporine and prednisone, which are routinely used following transplantation, and those not given drugs to dampen the immune system's rejection of the graft. In dogs not receiving the drugs, infiltration of the graft by indium-111 lymphocytes began about six days after the transplant.
The most profound barrier to pig-to-primate xenotransplantation is the rejection of the grafted organ by a cascade of immune mechanisms commonly referred to as hyperacute rejection (HAR), acute vascular rejection (AVR)/humoral xenograft rejection (AHXR), immune cell-mediated rejection, and chronic rejection.